Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lipson, E.J.; Drake, C.G. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clin. Cancer Res. 2011, 17, 6958–6962. [Google Scholar] [CrossRef] [Green Version]
- Ribas, A.; Wolchok, J.D. Cancer Immunotherapy Using Checkpoint Blockade. Science 2018, 359, 1350–1355. [Google Scholar] [CrossRef] [Green Version]
- Qin, S.; Xu, L.; Yi, M.; Yu, S.; Wu, K.; Luo, S. Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol. Cancer 2019, 18, 155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fujiwara, Y.; Kato, S.; Nesline, M.K.; Conroy, J.M.; De Pietro, P.; Pabla, S.; Kurzorck, R. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022, 110, 102461. [Google Scholar] [CrossRef] [PubMed]
- Yadav, R.; Redmond, W.L. Current Clinical Trial Landscape of OX40 Agonists. Curr. Oncol. Rep. 2022, 24, 951–960. [Google Scholar] [CrossRef]
- Kubo, T.; Sugawara, T.; Shinkawa, T.; Kurisu, T.; Kouzen, N.; Tanaka, T.; Fukuta, F.; Yamasaki, K.; Sugita, S.; Matsuo, K.; et al. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma. Immunol. Med. 2021, 44, 136–141. [Google Scholar] [CrossRef]
- Brahmer, J.R.; Lacchetti, C.; Schneider, B.J.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; Ernstoff, M.S.; Gardner, J.M.; Ginex, P.; et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018, 36, 1714–1768. [Google Scholar] [CrossRef]
- Haanen, J.; Obeid, M.; Spain, L.; Carbonnel, F.; Wang, Y.; Robert, C.; Lyon, A.R.; Wick, W.; Kostine, M.; Peters, S.; et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022, 33, 1217–1238. [Google Scholar] [CrossRef] [PubMed]
- Puzanov, I.; Diab, A.; Abdallah, K.; Bingham, C.O.; Brogdon, C.; Dadu, R.; Hamad, L.; Kim, S.; Lacouture, M.E.; LeBoeuf, N.R.; et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 2017, 5, 95. [Google Scholar] [CrossRef] [Green Version]
- Dougan, M.; Wang, Y.; Rubio-Tapia, A.; Lim, J.K. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 2021, 160, 1384–1393. [Google Scholar] [CrossRef]
- Thompson, J.A.; Schneider, B.J.; Brahmer, J.; Andrews, S.; Armand, P.; Bhatia, S.; Budde, L.E.; Costa, L.; Davies, M.; Dunnington, D.; et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J. Natl. Compr. Cancer Netw. 2020, 18, 230–241. [Google Scholar] [CrossRef] [Green Version]
- Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S.; et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372, 2006–2017. [Google Scholar] [CrossRef] [Green Version]
- Karamchandani, D.M.; Chetty, R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: Pathologists’ perspective. J. Clin. Pathol. 2018, 71, 665–671. [Google Scholar] [CrossRef]
- US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2017. Available online: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (accessed on 12 November 2022).
- Xing, H.; Wang, Y.; Qu, B.; Wei, Q.; Li, C.; Pan, C.; Li, H. The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Transl. Oncol. 2023, 1, 101619. [Google Scholar] [CrossRef]
- Terziroli Beretta-Piccoli, B.; Mieli-Vergani, G.; Vergani, D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J. Gastroenterol. 2017, 23, 6030–6048. [Google Scholar] [CrossRef] [PubMed]
- Remash, D.; Prince, D.S.; McKenzie, C.; Strasser, S.I.; Kao, S.; Liu, K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J. Gastroenterol. 2021, 27, 5376–5391. [Google Scholar] [PubMed]
- Ueno, M.; Takabatake, H.; Hata, A.; Kayahara, T.; Morimoto, Y.; Notohara, K.; Mizuno, M. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. Cancer Rep. 2022, 5, 1624. [Google Scholar] [CrossRef]
- Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015, 373, 23–34. [Google Scholar] [CrossRef] [Green Version]
- Wang, W.; Lie, P.; Guo, M.; He, J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. Int. J. Cancer 2017, 141, 1018–1028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ziogas, D.C.; Gkoufa, A.; Cholongitas, E.; Diamantopoulos, P.; Anastasopoulou, A.; Ascierto, P.A.; Gogas, H. When steroids are not enough in immune-related hepatitis: Current clinical challenges discussed on the basis of a case report. J. Immunother. Cancer 2020, 8, e001322. [Google Scholar] [CrossRef]
- Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015, 372, 2521–2532. [Google Scholar] [CrossRef]
- Lebbé, C.; Meyer, N.; Mortier, L.; Marquez-Rodas, I.; Robert, C.; Rutkowski, P.; Menzies, A.; Eigentler, T.; Ascierto, P.O.; Smylie, M.; et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination with Ipilimumab in Patients with Advanced Melanoma: Results from the Phase IIIb/IV CheckMate 511 Trial. J. Clin. Oncol. 2019, 37, 867–875. [Google Scholar] [CrossRef] [PubMed]
- Tawbi, H.A.; Schadendorf, D.; Lipson, E.J.; Ascierto, P.A.; Matamala, L.; Gutiérrez, E.C.; Rutkowski, P.; Gogas, H.J.; Lao, C.D.; De Menezes, J.J.; et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N. Engl. J. Med. 2022, 386, 24–34. [Google Scholar] [CrossRef] [PubMed]
- BSMO. Immunomanager, Hepatitis. Available online: https://www.bsmo.be/immunomanager/start/hepatitis (accessed on 6 June 2022).
- McIlwaine, S.; Cullen, A.; Stratton, L.; Oladipo, B.; Cash, J.; Carser, J.; Braniff, C. The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis. J. R. Coll. Physicians Edinb. 2022, 52, 20–23. [Google Scholar] [CrossRef]
- Martin, E.D.; Michot, J.M.; Papouin, B.; Champiat, S.; Mateus, C.; Lambotte, O.; Roche, B.; Antonini, T.M.; Coil, A.; Laghouati, S.; et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 2018, 68, 1181–1190. [Google Scholar] [CrossRef]
- Gauci, M.L.; Baroudjian, B.; Zeboulon, C.; Pages, C.; Poté, N.; Roux, O.; Bouattour, M.; Lebbé, C. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? J. Hepatol. 2018, 69, 548–550. [Google Scholar] [CrossRef]
- Cheung, V.; Gupta, T.; Payne, M.; Middleton, M.R.; Collier, J.D.; Simmons, A.; Klenerman, P.; Brain, O.; Cobbold, J.F. Immunotherapy-related hepatitis: Real-world experience from a tertiary centre. Frontline Gastroenterol. 2019, 10, 364–371. [Google Scholar] [CrossRef]
- Horvat, T.Z.; Adel, N.G.; Dang, T.O.; Momtaz, P.; Postow, M.A.; Callahan, M.K.; Carvajjal, R.D.; Dickson, M.A.; D’Angelo, S.P.; Woo, K.M.; et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients with Melanoma Treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 2015, 33, 3193–3198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allison, A.C.; Eugui, E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47, 85–118. [Google Scholar] [CrossRef]
- Cara, C.J.; Pena, A.S.; Sans, M.; Rodrigo, L.; Guerrero-Esteo, M.; Hinojosa, J.; García-Paredes, J.; Guijarro, L.G. Reviewing the mechanism of action of thiopurine drugs: Towards a new paradigm in clinical practice. Med. Sci. Monit. 2004, 10, 247–254. [Google Scholar]
- Warty, V.; Zuckerman, S.; Venkataramanan, R.; Lever, J.; Fung, J.; Starzl, T. FK506 Measurement: Comparison of Different Analytical Methods. Ther. Drug Monit. 1993, 15, 204–208. [Google Scholar] [CrossRef] [PubMed]
- Burra, P.; Burroughs, A.; Graziadei, I.; Pirenne, J.; Valdecasas, C.J.; Muiesan, P.; Samuel, D.; Forns, X. EASL Clinical Practice Guidelines: Liver transplantation. J. Hepatol. 2016, 64, 433–485. [Google Scholar]
- Hirasawa, Y.; Yoshimura, K.; Matsui, H.; Kubota, Y.; Ishida, H.; Arai, J.; Sakaki, M.; Oguro, N.; Shida, M.; Taniguchi, M.; et al. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine 2021, 100, e25774. [Google Scholar] [CrossRef]
- Nakashima, K.; Demura, Y.; Oi, M.; Tabata, M.; Tada, T.; Shiozaki, K.; Akai, K.; Ishizuka, T. Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab. Intern. Med. 2020, 59, 3055–3059. [Google Scholar] [CrossRef]
- Chmiel, K.D.; Suan, D.; Liddle, C.; Nankivell, B.; Ibrahim, R.; Bautista, C.; Thompson, J.; Fulcher, D.; Kefford, R. Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29, e237-40. [Google Scholar] [CrossRef]
- Ahmed, T.; Pandey, R.; Shah, B.; Black, J. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. 2015, 2015, bcr2014208102. [Google Scholar] [CrossRef] [Green Version]
- Spänkuch, I.; Gassenmaier, M.; Tampouri, I.; Noor, S.; Forschner, A.; Garbe, C.; Amaral, T. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur. J. Cancer 2017, 81, 203–205. [Google Scholar] [CrossRef]
- McGuire, H.M.; Shklovskaya, E.; Edwards, J.; Trevillian, P.R.; McCaughan, G.W.; Bertolino, P.; McKenzie, C.; Gourlay, R.; Gallagher, S.J.; Fazekas de St. Groth, B.; et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: A case report. Cancer Immunol. Immunother. 2018, 67, 563–573. [Google Scholar] [CrossRef] [Green Version]
- Stroud, C.R.; Hegde, A.; Cherry, C.; Naqash, A.R.; Sharma, N.; Addepalli, S.; Cherukuri, S.; Parent, T.; Hardin, J.; Walker, P. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J. Oncol. Pharm. Pract. 2019, 25, 551–557. [Google Scholar] [CrossRef]
- Moi, L.; Bouchaab, H.; Mederos, N.; Nguyen-Ngoc, T.; Perreau, M.; Fenwick, C.; Vaucher, J.; Sempoux, C.; Peters, S.; Obeid, M. Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis. J. Thorac. Oncol. 2021, 16, 318–326. [Google Scholar] [CrossRef]
- Abdel-Wahab, N.; Montazari, E.; Spillson, C.; Bentebibel, S.E.; Awiwi, M.; Elsayes, K.M.; Gao, J.; Altan, M.; Wong, M.K.K.; Glitza, I.C.; et al. Tocilizumab in combination with ipilimumab and nivolumab in solid tumors. J. Clin. Oncol. 2022, 40, TPS9600. [Google Scholar] [CrossRef]
- NYU Langone Health. A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma. Clinicaltrials.gov; 2023. Report No.: NCT03999749. Available online: https://clinicaltrials.gov/ct2/show/NCT03999749 (accessed on 2 February 2023).
- Haanen, J.; Ernstoff, M.; Wang, Y.; Menzies, A.; Puzanov, I.; Grivas, P.; Larkin, J.; Peters, S.; Thompson, J.; Obeid, M. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: Review of the literature and suggested prophylactic strategy. J. Immunother. Cancer. 2020, 8, e000604. [Google Scholar] [CrossRef] [PubMed]
- Ghembaza, A.; Vautier, M.; Cacoub, P.; Pourcher, V.; Saadoun, D. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients with Autoimmune and Inflammatory Diseases. Chest 2020, 158, 2323–2332. [Google Scholar] [CrossRef] [PubMed]
- Ramírez-Carmona, W.; Fernandes, G.L.P.; Díaz-Fabregat, B.; Oliveira, E.C.; do Prado, R.L.; Pessan, J.P.; Monteiro, D.R. Effectiveness of fluconazole as antifungal prophylaxis in cancer patients undergoing chemotherapy, radiotherapy, or immunotherapy: Systematic review and meta-analysis. J. Pathol. Microbiol. Immunol. 2023; early view. [Google Scholar]
- Lalla, R.V.; Latortue, M.C.; Hong, C.H.; Ariyawardana, A.; D’Amato-Palumbo, S.; Fischer, D.J.; Martof, A.; Nicolatou-Galitis, O.; Patton, L.L.; Elting, L.S.; et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 2010, 18, 985–992. [Google Scholar] [CrossRef] [Green Version]
- Teh, B.W.; Yeoh, D.K.; Haeusler, G.M.; Yannakou, C.K.; Fleming, S.; Lindsay, J.; Slavin, M.A. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation. Intern. Med. J. 2021, 51, 67–88. [Google Scholar] [CrossRef]
- Zahid, M.F.; Ghufran, M.; Mansoor, A.e.R.; Sohail, M.R. Herpes zoster during immunosuppressive therapy for autoimmune diseases. J. Ayub Med. Coll. Abbottabad 2017, 29, 483–487. [Google Scholar]
- Van Not, O.; Verheijden, R.; van den Eertwegh, A.; Haanen, J.; Aarts, M.; van den Berkmortel, F.; Blank, C.U.; Boers-Sonderen, M.J.; de Groot, J.B.; Hospers, G.; et al. Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma. JAMA Oncol. 2022, 8, 1794–1801. [Google Scholar] [CrossRef]
- Serna-Higuita, L.M.; Amaral, T.; Forschner, A.; Leiter, U.; Flatz, L.; Seeber, O.; Thomas, I.; Garbe, C.; Eigentler, T.K.; Martus, P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers 2021, 13, 6141. [Google Scholar] [CrossRef]
AST or ALT | GGT or ALP | Bilirubin | |
---|---|---|---|
Grade 1 | 1–3 × ULN | 1–2.5 × ULN | 1–1.5 × ULN |
Grade 2 | 3–5 × ULN | 2.5–5 × ULN | 1.5–3 × ULN |
Grade 3 | 5–20 × ULN | 5–20 × ULN | 3–10 × ULN |
Grade 4 | >20 × ULN | >20 × ULN | >10 × ULN |
Grade 5 | death |
Author [Citation] + Median Follow-Up | Anti-CTLA-4 Monotherapy | Anti-PD-1 Monotherapy | Standard Combination Therapy | Flip Dose Regimen Combination Therapy | Relatlimab-Based Combination Therapy |
---|---|---|---|---|---|
Postow et al. [12] Not reported † | Any 2/46 (4%) G3≥ 0/46 (0%) | N/A | Any 21/96 (22%) G3≥ 10/96 (11%) | N/A | N/A |
Larkin et al. [19] 12.3 months | Any 12/311 (3.9%) G3≥ 5/311 (1.6%) | Any 12/313 (3.8%) G3≥ 4/313 (1.3%) | Any 55/313 (17.6%) G3≥ 26/313 (8.3%) | N/A | N/A |
Robert et al. [22] 7.9 months | Any 3/256 (1.2%) G3≥ 1/256 (0.4%) | Any 5/277 (1.8%) * G3≥ 5/277 (1.8%) * | N/A | N/A | N/A |
Lebbé et al. [23] 18.7 months | N/A | N/A | Any 32/178 (18%) G3≥ 8/178 (4.5%) | Any 16/180 (8.9%) G3≥ 3/180 (1.7%) | N/A |
Tawbi et al. [24] 13.2 months | N/A | Any 9/359 (2.5%) ° G3≥ 4/359 (1.1%) ° | N/A | N/A | Any 20/355 (5.6%) G3≥ 14/355 (4.9%) |
Guidelines [Citations] | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
---|---|---|---|---|
Consensus between the different guidelines | Continue ICI Clinical work-up (includ-ing review of medication, alcohol and food) No treatment for irH needed | Withhold until ≤ grade 1 FU once to twice weekly Add lab/imaging work-up if not yet added Rechallenge if grade ≤ 1 and prednisone ≤ 10 mg/day | Discontinue Promptly start steroids (at least 1 mg/kg/day) FU at least every 2 days Consider biopsy Taper over 4–6 weeks once ≤ grade 2 | Permanently discontinue Promptly start steroids iv (at least 2 mg/kg/day) Daily labs (in hospital) Strongly consider biopsy Taper over ≥4–6 weeks once ≤ grade 2 |
SITC [9] | Monitor lab results weekly | Always start steroids at 0.5 mg/kg/day prednisone Taper over 1 month Biopsy is optional | If no improvement after 3 days start MMF | Same as grade 3 |
ASCO [7] | Monitor lab results weekly | Start steroids if irH persists for 3–5 days Further recommendations as SITC (but no biopsy) | Like STIC, but (if TMPT is normal) azathioprine can be considered | Same as grade 3 |
AGA [10] | Monitor lab results 1–2 times weekly Postponing therapy can be considered Consider MRCP or echo-endoscopy if negative US | Consider 0.5–1 mg/kg/day prednisone (if symptoms) If no resolution after 1–2 weeks start steroids Consider biopsy before starting steroids | If no improvement after 3–5 days consider MMF, azathioprine or tacrolimus Infliximab should only be considered with caution | In fulminant cases consider ATG |
NCCN [11] | Monitor lab results with increased frequency Consider MRCP if negative ultrasound | Consider 0.5–1 mg/kg/day prednisone (no time defined) Further recommendations as SITC (but no biopsy) | Like STIC Advise against infliximab | Same as grade 3 |
ESMO [8] | Work-up not strictly mandatory | If irH persist > 1 week or rises 0.5–1 mg/kg/day prednisone Taper over 2 weeks once grade ≤ 1 | If AST or ALT > 400 U/L or in case of disturbed LF: iv 2 mg/kg/day prednisone If worsening on iv steroids add MMF and as needed tacrolimus | ATG can be considered in MMF-refractory cases as alternative to tacrolimus, cyclosporin, azathioprine or tocilizumab |
BSMO [25] | Lab work-up (including lipase/creatinine kinase) and consider imaging Postpone 1 week if rising bilirubin or if any doubt | No steroids unless rising bilirubin | If AST and AST < 10 × ULN and bilirubin < 3 × ULN in anti-PD-(L)1: no steroids If worsening on iv steroids add MMF and as needed tacrolimus Rechallenge only after positive MDC | If bilirubin not rising (<3 × ULN) and normal INR and albumin and no hypoglycemia: 1 mg/kg/day po If MMF-refractory ATG is alternative to tacrolimus Rechallenge questionable |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
De Wilde, R.; Saerens, M.; Hoorens, A.; Geerts, A.; Jacobs, C. Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature. Int. J. Transl. Med. 2023, 3, 274-285. https://doi.org/10.3390/ijtm3030019
De Wilde R, Saerens M, Hoorens A, Geerts A, Jacobs C. Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature. International Journal of Translational Medicine. 2023; 3(3):274-285. https://doi.org/10.3390/ijtm3030019
Chicago/Turabian StyleDe Wilde, Ruben, Michael Saerens, Anne Hoorens, Anja Geerts, and Celine Jacobs. 2023. "Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature" International Journal of Translational Medicine 3, no. 3: 274-285. https://doi.org/10.3390/ijtm3030019